Prediction market wagering on drug approvals draws fire from researchers

Betting platforms Kalshi and Polymarket are allowing users to wager on FDA drug approvals and clinical trial outcomes, sparking criticism from researchers, doctors, and patients over risks to scientific integrity and public trust. Critics argue prediction markets could influence trial behavior and enable insider trading, while Kalshi claims they offer valuable insights and have safeguards against insider participation.